OncoMatch/Clinical Trials/NCT06554652
Selective Neck Dissection Versus Modified Neck Dissection in PTC
Is NCT06554652 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies non-drug interventions for thyroid cancer.
This study is a phase III, randomized controlled, open label non inferiority study. Patients who meet the inclusion criteria are randomly assigned 1:1 to either the experimental group (selective neck dissection) or the control group (modified neck dissection), with LRFS as the primary endpoint. The aim of the study is to evaluate the safety of selective neck dissection in papillary carcinoma with limited number of lymph node metastases in the lateral neck, and the quality of life compared with modified neck dissection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Demographics
Prior therapy
Cannot have received:
Exception: endocrine therapy
Previous treatment for thyroid cancer other than endocrine therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06554652 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify